These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21487080)

  • 1. Acute pancreatitis associated with liraglutide.
    Lee PH; Stockton MD; Franks AS
    Ann Pharmacother; 2011 Apr; 45(4):e22. PubMed ID: 21487080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liraglutide-associated acute pancreatitis.
    Knezevich E; Crnic T; Kershaw S; Drincic A
    Am J Health Syst Pharm; 2012 Mar; 69(5):386-9. PubMed ID: 22345417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
    Alves C; Batel-Marques F; Macedo AF
    Diabetes Res Clin Pract; 2012 Nov; 98(2):271-84. PubMed ID: 23010561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatitis: a potential complication of liraglutide?
    Franks AS; Lee PH; George CM
    Ann Pharmacother; 2012 Nov; 46(11):1547-53. PubMed ID: 23136352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liraglutide. Type 2 diabetes: more prudent to continue using exenatide.
    Prescrire Int; 2010 Jun; 19(107):109-12. PubMed ID: 20738033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liraglutide-induced acute pancreatitis.
    Jeyaraj S; Shetty AS; Kumar CR; Nanditha A; Krishnamoorthy S; Raghavan A; Raghavan K; Ramachandran A
    J Assoc Physicians India; 2014 Jan; 62(1):64-6. PubMed ID: 25327099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of pancreatitis with glucagon-like peptide-1 agonist use.
    Anderson SL; Trujillo JM
    Ann Pharmacother; 2010 May; 44(5):904-9. PubMed ID: 20371755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
    Malmenäs M; Bouchard JR; Langer J
    Clin Ther; 2013 Jun; 35(6):795-807. PubMed ID: 23642290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liraglutide-induced acute kidney injury.
    Kaakeh Y; Kanjee S; Boone K; Sutton J
    Pharmacotherapy; 2012 Jan; 32(1):e7-11. PubMed ID: 22392833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.
    Miller LA; Burudpakdee C; Zagar A; Bhosle M; Reaney M; Schabert VF; Bruhn D
    J Med Econ; 2012; 15(4):746-57. PubMed ID: 22443463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
    Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
    Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E; Sesti G
    Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.
    Chalmer T; Almdal TP; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2015 Jan; 14(1):171-80. PubMed ID: 25363438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide and rare adverse events.
    Ahmad SR; Swann J
    N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920
    [No Abstract]   [Full Text] [Related]  

  • 19. Liraglutide: from clinical trials to clinical practice.
    Gough SC
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
    Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
    J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.